Randomized clinical trials in hepatocellular carcinoma.

Area of Science:

• Hepatology
• Surgical Oncology
• Gastroenterology

Background:

• Hepatocellular carcinoma (HCC) is a prevalent solid tumor and a major cause of cancer mortality worldwide.
• Many patients are diagnosed with advanced-stage HCC and co-existing chronic liver dysfunction, restricting treatment choices.
• Current surveillance programs have limitations in early detection for effective intervention.

Purpose of the Study:

• To review key randomized controlled trials (RCTs) on surgical and adjuvant interventions for hepatocellular carcinoma.
• To provide an evidence-based overview of treatments that influence the current management algorithm for HCC.
• To synthesize data on the efficacy of various therapeutic strategies in advanced HCC.

Main Methods:

• Systematic review of pertinent randomized controlled trials.
• Analysis of studies focusing on surgical resection, liver transplantation, and adjuvant therapies.
• Evaluation of treatment outcomes in patients with hepatocellular carcinoma.

Main Results:

• Surgical interventions, such as resection and transplantation, remain critical for resectable HCC.
• Adjuvant therapies show variable efficacy, with ongoing research to define their role in improving outcomes.
• Treatment decisions are heavily influenced by tumor stage and patient's hepatic functional reserve.

Conclusions:

• The management of hepatocellular carcinoma requires a multidisciplinary approach, balancing surgical options with adjuvant strategies.
• Evidence from RCTs is crucial for refining treatment algorithms and improving survival rates in HCC patients.
• Further research is needed to optimize adjuvant therapies and manage advanced-stage disease effectively.